Amir Fathi, MD, is program director of the Center for Leukemia at Massachusetts General Hospital; as well as an associate professor of medicine at Harvard Medical School
Amir T. Fathi, MD, presents a multicenter retrospective cohort study demonstrating that intensive chemotherapy plus quizartinib was associated with superior 1-year overall survival (93% vs 78%; adjusted HR, 0.19) and event-free survival compared with intensive chemotherapy plus midostaurin in patients with newly diagnosed FLT3-ITD–mutated acute myeloid leukemia.
Amir Fathi, MD, discusses findings with ziftomenib in patients with relapsed/refractory, NPM1-mutant acute myeloid leukemia as demonstrated in KOMET-001.
Amir Fathi, MD, discusses findings from the phase 1b expansion portion of the phase 1/2 KOMET-001 trial in patients with relapsed/refractory acute myeloid leukemia harboring NPM1 mutations.
